Binds Enzyme Patents (Class 530/388.26)
-
Publication number: 20070269442Abstract: A chimeric therapeutic agent recognizing iNOS utilizing a human/mouse chimeric anti-hiNOS monoclonal antibody having mouse complimentarity-determining regions forming a binding site for iNOS.Type: ApplicationFiled: May 19, 2006Publication date: November 22, 2007Inventors: Robert J. Webber, Douglas S. Webber, Thelma H. Dixon
-
Patent number: 7297336Abstract: Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.Type: GrantFiled: September 12, 2003Date of Patent: November 20, 2007Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger
-
Patent number: 7294705Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 24, 2002Date of Patent: November 13, 2007Assignee: Genetech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7279290Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.Type: GrantFiled: November 23, 2005Date of Patent: October 9, 2007Assignee: St. Jude Children's Research HospitalInventors: Michael B. Kastan, Christopher Bakkenist
-
Patent number: 7279274Abstract: Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of the expression of a diabetes-mediating protein.Type: GrantFiled: October 7, 2004Date of Patent: October 9, 2007Assignee: Pride Proteomics A/SInventors: Peter Mose Larsen, Stephen J. Fey, Allan E. Karlsen, Thomas Sparre, Jorn Nerup
-
Patent number: 7276375Abstract: A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.Type: GrantFiled: September 30, 2004Date of Patent: October 2, 2007Assignees: Medical & Biological Laboratories Co., Ltd.Inventors: Yasuhisa Fukui, Satoshi Nagata, Ryuichi Shirai
-
Patent number: 7273610Abstract: Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.Type: GrantFiled: August 12, 2004Date of Patent: September 25, 2007Assignee: Dyax Corp.Inventors: Andrew Nixon, Edwin L. Madison
-
Patent number: 7264932Abstract: Methods and compositions for inhibiting and/or inactivating nucleases by using nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors.Type: GrantFiled: February 25, 2004Date of Patent: September 4, 2007Assignee: Applera CorporationInventors: Gary J. Latham, Matthew M. Winkler, Brittan L. Pasloske, W. Antoni Kudlicki
-
Patent number: 7247442Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: May 21, 2004Date of Patent: July 24, 2007Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Kimberly A. Florence, Jian Ni, Craig A. Rosen, Kenneth C. Carter, Paul A. Moore, Henrik S. Olsen, Yanggu Shi, Paul E. Young, Ying-Fei Wei, Laurie A. Brewer, Daniel R. Soppet, David W. LaFleur, Gregory A. Endress, Reinhard Ebner, Charles E. Birse
-
Patent number: 7232661Abstract: This invention is about a method for the prenatal diagnosis of preterm delivery, fetal infection, and fetal damage, and diagnostic reagent system and diagnostic kit for the diagnosis. The method, diagnostic reagent system, and kit are based on the finding that the level of MMP-8 in the amniotic fluid is significantly higher when the pregnant woman is at risk for preterm delivery, intrauterine infection, and fetal damage. The diagnostic reagent system and kit can be applied to patients with or without clinical signs of preterm labor or premature rupture of fetal membranes. With its superiority in sensitivity and specificity as well as its less invasiveness compared to the conventional method of measuring fetal blood cytokine levels, this diagnostic reagent system and kit is very useful in the prenatal diagnosis of preterm delivery, fetal infection, and fetal damage.Type: GrantFiled: August 1, 2001Date of Patent: June 19, 2007Assignee: Seoul National University Industry FoundationInventor: Bo Hyun Yoon
-
Patent number: 7214373Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.Type: GrantFiled: July 23, 2002Date of Patent: May 8, 2007Assignee: Yale UniversityInventors: Jack A. Elias, Zhou Zhu
-
Patent number: 7195926Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: March 8, 2000Date of Patent: March 27, 2007Assignee: Incyte CorporationInventors: Roger Coleman, Scott Michael Braxton, Jeffrey J. Seilhamer
-
Patent number: 7189823Abstract: Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.Type: GrantFiled: May 20, 2005Date of Patent: March 13, 2007Assignee: University of PittsburghInventors: Anthony J. Bauer, Gisela Bruenagel, Robert H. Getzenberg, Robert E. Schoen
-
Patent number: 7183110Abstract: Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.Type: GrantFiled: December 16, 1999Date of Patent: February 27, 2007Assignee: Monsanto Technology LLCInventors: Gerard Francis Barry, Ganesh Murthy Kishore, Stephen Rogers Padgette, William Carlton Stallings
-
Patent number: 7176291Abstract: The present invention provides two unique monoclonal antibodies directed against a portion of the human Glycine N-methyltransferase, and methods of use for the monoclonal antibodies in detecting, monitoring and diagnosing malignancies characterized by down-regulation of expression or inappropriate expression of the Glycine N-methyltransferase.Type: GrantFiled: November 22, 2002Date of Patent: February 13, 2007Assignee: Gene Research Lab. Co., Ltd.Inventor: Yi-Ming A. Chen
-
Patent number: 7169759Abstract: Statine-derived peptide inhibitors of the ?-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A? peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce A? peptide formation and pharmaceutical compositions.Type: GrantFiled: June 15, 2000Date of Patent: January 30, 2007Assignee: Elan Pharmaceuticals, Inc.Inventors: Varghese John, Jay Tung, Lawrence Fang, Shumeye S. Mamo
-
Patent number: 7169566Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.Type: GrantFiled: November 2, 2004Date of Patent: January 30, 2007Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Steven M. Ruben, Laurie A. Brewer, Reiner L. Gentz, Craig A. Rosen
-
Patent number: 7157237Abstract: The present invention provides antigenic peptides useful for the production of antibodies which selectively bind to an enzyme involved in the ?-oxidation of fatty acids and alkanes to ?,?-dicarboxylic acids in yeast. Antibodies which specifically bind to an enzyme involved in the ?-oxidation of fatty acids and alkanes to ?,?-dicarboxylic acids in yeast are also provided. In addition, methods of producing the subject antibodies, a method of detecting the presence and amount of a specific enzyme involved in the ?-oxidation of fatty acids and alkanes to ?,?-dicarboxylic acids, and a method of monitoring the degree of enzyme induction and/or enzyme stability in a mixture during ?-oxidation of fatty acids and alkanes to ?,?-dicarboxylic acids in yeast, are also provided.Type: GrantFiled: April 18, 2003Date of Patent: January 2, 2007Assignee: Cognis CorporationInventors: Yeyan Zhang, C. Ron Wilson
-
Patent number: 7153941Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 10, 2002Date of Patent: December 26, 2006Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7148063Abstract: The object of the present invention is to provide a method for more accurately assaying the enzyme activities of mCK isozymes and a method for separately assaying the enzyme activities of CK isozymes by separately assaying the enzyme activities of ubiquitous mCK (umCK) and sarcomeric mCK (smCK). The above object is attained by an assay using an antibody that specifically recognizes umCK protein. In addition, other anti-mCK antibodies (e.g., anti-smCK antibody) and/or anti-human CK-M-inhibiting antibody can also be used. The above antibody is a polyclonal antibody or a monoclonal antibody. As a result of these antibodies, a monoclonal antibody (U1-1881) that is capable of specifically recognizing human umCK and is produced by a hybridoma having a deposition number of FERM BP-8342 is provided.Type: GrantFiled: April 29, 2003Date of Patent: December 12, 2006Assignee: Sysmex CorporationInventors: Yasushi Shirahase, Tadahiro Kajita, Koji Kishi, Kazuaki Yamashita
-
Patent number: 7141652Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 24, 2002Date of Patent: November 28, 2006Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7135555Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: May 14, 2002Date of Patent: November 14, 2006Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 7115715Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).Type: GrantFiled: September 27, 2001Date of Patent: October 3, 2006Assignee: Institute of Virology Slovak Academy of SciencesInventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 7115382Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A) are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents are also described.Type: GrantFiled: March 15, 2000Date of Patent: October 3, 2006Assignees: Mayo Foundation for Medical Education and Research, Como Holdings APSInventors: Michael Toft Overgaard, Claus Oxvig, Cheryl A. Conover
-
Patent number: 7112325Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme, antibodies to such enzyme, and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.Type: GrantFiled: July 1, 2003Date of Patent: September 26, 2006Assignee: Genetics Institute, LLCInventors: Simon Jones, Jin Tang
-
Patent number: 7108992Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.Type: GrantFiled: November 27, 2002Date of Patent: September 19, 2006Assignee: St. Jude Children's Research HospitalInventors: Michael B. Kastan, Christopher Bakkenist
-
Patent number: 7105330Abstract: The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression. The invention additionally features methods of treating tumor-bearing patients by administration of hpHAse and/or transformation of cells with hpHAse-encoding DNA.Type: GrantFiled: July 18, 2003Date of Patent: September 12, 2006Assignee: The Regents of the University of CaliforniaInventors: Robert Stern, Gregory I. Frost, Anthony Csoka, Tim M. Wong
-
Patent number: 7101680Abstract: A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.Type: GrantFiled: October 4, 2001Date of Patent: September 5, 2006Assignee: Syn X Pharma, Inc.Inventors: George Jackowski, Miyoko Takahashi
-
Patent number: 7101675Abstract: A modulator of regulatory cellular events occurring intracellularly which are mediated by regulatory proteins containing a ‘death domain’ motif is provided. The ‘death domain’ is a regulatory portion of the regulatory proteins, and the modulator is capable of interacting with one or more ‘death domain’ motifs contained in the regulatory proteins and affecting the regulatory action of one or more of the regulatory proteins. The modulator preferably is capable of interacting with ‘death domain’ motifs within p55-TNF-R, FAS/APO1-R, NGF-R, MORT-1, RIP, TRADD, or ankyrin. A method for producing the modulators is also provided. The modulators are useful for modulating functions mediated in cells by proteins containing the ‘death domain’.Type: GrantFiled: January 4, 2002Date of Patent: September 5, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Mark P Boldin, Eugene E Varfolomeev, Zeev Pancer, Igor Mett, Tanya M Goncharov
-
Patent number: 7094881Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.Type: GrantFiled: August 14, 2003Date of Patent: August 22, 2006Assignee: Applera CorporationInventors: Ellen M Beasley, Zhenya Li
-
Patent number: 7091323Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.Type: GrantFiled: April 24, 2002Date of Patent: August 15, 2006Assignees: Bayer Corporation, Bayer AktiengesellschaftInventors: Clark Pan, Andreas M. Knorr, Michael Schauer, Claudia Hirth-Dietrich, Sabine Kraft, Barbara Krebs
-
Patent number: 7083786Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.Type: GrantFiled: June 4, 2001Date of Patent: August 1, 2006Inventors: Jens Chr. Jensenius, Steffen Thiel
-
Patent number: 7081519Abstract: Antibodies that specifically bind to novel serine protease polypeptides are disclosed. The polypeptides are selected from the group consisting of a polypeptide as shown in SEQ ID NO:2 from residue 1 through residue 373, a polypeptide as shown in SEQ ID NO:15 from residue 1 through residue 373, and a polypeptide as shown in SEQ ID NO:18 from residue 1 through residue 364.Type: GrantFiled: September 8, 2000Date of Patent: July 25, 2006Assignee: ZymoGenetics, Inc.Inventor: Paul O. Sheppard
-
Patent number: 7078491Abstract: The present invention relates to novel selective binding agents including polyclonal and monoclonal antibodies that recognize and bind to the catalytic subunit of human telomerase (hTERT). The invention also relates to the production, diagnostic use, and therapeutic use of the hTERT antibodies and fragments thereof.Type: GrantFiled: September 20, 2001Date of Patent: July 18, 2006Assignee: Amgen Inc.Inventor: Lea A. Harrington
-
Patent number: 7074903Abstract: Monocolonal antibodies having a higher reactivity with tartrate-resistant acid phosphatase 5b (TRACP 5b) than tartrate-resistant acid phosphatase 5a (TRACP 5a) and having a higher specificity to TRACP 5b can be obtained by cell fusion using as antigens TRACP 5b purified from human osteoclasts. By using the monoclonal antibody, TRACP 5b in a sample can be detected specifically with a high sensitivity.Type: GrantFiled: April 29, 2003Date of Patent: July 11, 2006Assignee: Nitto Boseki Co., Ltd.Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Kumiko Sasagawa, Katsuhiro Katayama
-
Patent number: 7074554Abstract: Materials and methods are provided to inhibit HIV replication in targeted host cells.Type: GrantFiled: December 10, 2003Date of Patent: July 11, 2006Assignee: The Board of Regents of the University of NebraskaInventors: Tsuneya Ikezu, Gary Leisman, Kimberly A. Carlson, Howard E. Gendelman
-
Patent number: 7070945Abstract: A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.Type: GrantFiled: September 17, 2002Date of Patent: July 4, 2006Assignee: Syn X Pharma, Inc.Inventors: George Jackowski, Miyoko Takahashi
-
Patent number: 7056718Abstract: The present invention relates to isolated polypeptides having oxaloacetate hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: GrantFiled: July 29, 2005Date of Patent: June 6, 2006Assignee: Novozymes, Inc.Inventors: Debbie Yaver, Barbara Cherry, Jeffrey Murrell
-
Patent number: 7053188Abstract: Compositions and methods for diagnosis of neoplastic tissue are described. Monoclonal antibodies which specifically recognize the tumor cell specific NADH:protein thiol reductase and the hybridoma cell lines which produce them are provided. Also provided are diagnostic and immunohistological assays for the identification of cells that are neoplastic.Type: GrantFiled: February 24, 2003Date of Patent: May 30, 2006Assignee: Purdue Research FoundationInventors: D. James Morré, NaMi McCarty, Dorothy Morré, Pin-Ju Chueh
-
Patent number: 7052890Abstract: The invention provides a nucleotide sequence comprising at least a portion of the nucleotide sequence of FIG. 10A, FIG. 6B or FIG. 10A or FIG. 10B; nucleotides which hybridise to the nucleotide sequences of FIG. 6A, FIG. 6B or FIG. 10A or FIG. 10B; nucleotides which are degenerate to the nucleotide sequences of FIG. 6A, FIG. 6B or FIG. 10A or FIG. 10B; all of which nucleotides encode a polypeptide having transglutaminase activity.Type: GrantFiled: September 14, 2001Date of Patent: May 30, 2006Assignee: University College Cardiff Consultants, Ltd.Inventors: Daniel Peter Aeschlimann, Pascale Marie Grenard
-
Patent number: 7049407Abstract: A variety of heparanase specific antibodies which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific antibodies for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific antibodies for therapy of a condition associated with expression of heparanase; the use of a heparanase specific antibodies for quantification of heparanase in a body fluid; the use of a heparanase specific antibodies for targeted drug delivery; and the use of a heparanase specific antibodies as a therapeutic agent.Type: GrantFiled: January 16, 2001Date of Patent: May 23, 2006Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Iris Pecker, Israel Vlodavsky, Yael Friedman, Tuvia Perets
-
Patent number: 7049412Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.Type: GrantFiled: August 9, 2000Date of Patent: May 23, 2006Assignee: Bristol-Myers Squibb Pharma Comp.Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
-
Patent number: 7026140Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.Type: GrantFiled: September 2, 2004Date of Patent: April 11, 2006Assignee: Human Genome Sciences, Inc.Inventors: Peter L. Hudson, Wei Wu He, Steven M. Ruben
-
Patent number: 7015008Abstract: The present invention features antibodies referred to herein as “MAb50-4” and “MAb184-10”, and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.Type: GrantFiled: September 25, 2001Date of Patent: March 21, 2006Assignee: Merck & Co., Inc.Inventors: Magang Shou, Qin Mei
-
Patent number: 6951923Abstract: This invention provides for antibodies directed to OLD-35 protein, the product of the OLD-35 gene, which displays enhanced expression during cellular senescence and terminal cell differentiation.Type: GrantFiled: July 16, 2001Date of Patent: October 4, 2005Assignee: Trustees of Columbia University in the City of New YorkInventors: Paul B. Fisher, Leszczyniecka Magdalena
-
Patent number: 6939701Abstract: The present invention relates to isolated polypeptides having oxaloacetate hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: GrantFiled: August 6, 2004Date of Patent: September 6, 2005Assignee: Novozymes, Inc.Inventors: Debbie Yaver, Barbara Cherry, Jeffrey Murrell
-
Patent number: 6933369Abstract: Nucleic acids encoding various proteases, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: January 22, 2003Date of Patent: August 23, 2005Assignee: Schering CorporationInventors: Christopher G. Mueller, Serge J. E. Lebecque, Yong-Jun Liu, Lynette M. Dowling, Constance F. Huffine, Daniel M. Gorman
-
Patent number: 6921658Abstract: There are provided a human BSSP6 serine protease and a pharmaceutical composition containing this serine protease. Also provided is an antibody to this serine protease or to a fragment thereof.Type: GrantFiled: November 19, 1999Date of Patent: July 26, 2005Assignee: Fuso Pharmacutical Industries, Ltd.Inventors: Hidetoshi Uemura, Akira Okui, Katsuya Kominami, Nozomi Yamaguchi, Shinichi Mitsui
-
Patent number: 6893831Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.Type: GrantFiled: June 1, 2000Date of Patent: May 17, 2005Assignee: Sanko Junyaku Co., Ltd.Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai
-
Patent number: 6890721Abstract: Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilize such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.Type: GrantFiled: September 24, 2001Date of Patent: May 10, 2005Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation, The Regents of the University of MichiganInventors: Vishva M. Dixit, Wei-Wu He, Kristine K. Kikly, Steven M. Ruben